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Abstract
Brain-derived neurotrophic factor (BDNF) importantly regulates learning and memory and supports the survival of injured
neurons. Reduced BDNF levels have been detected in the brains of Alzheimer’s disease (AD) patients but the exact role of
BDNF in the pathophysiology of the disorder remains obscure. We have recently shown that reduced signaling of BDNF
receptor TrkB aggravates memory impairment in APPswe/PS1dE9 (APdE9) mice, a model of AD. The present study examined
the influence of Bdnf gene deficiency (heterozygous knockout) on spatial learning, spontaneous exploratory activity and
motor coordination/balance in middle-aged male and female APdE9 mice. We also studied brain BDNF protein levels in
APdE9 mice in different ages showing progressive amyloid pathology. Both APdE9 and Bdnf mutations impaired spatial
learning in males and showed a similar trend in females. Importantly, the effect was additive, so that double mutant mice
performed the worst. However, APdE9 and Bdnf mutations influenced spontaneous locomotion in contrasting ways, such
that locomotor hyperactivity observed in APdE9 mice was normalized by Bdnf deficiency. Obesity associated with Bdnf
deficiency did not account for the reduced hyperactivity in double mutant mice. Bdnf deficiency did not alter amyloid
plaque formation in APdE9 mice. Before plaque formation (3 months), BDNF protein levels where either reduced (female) or
unaltered (male) in the APdE9 mouse cortex. Unexpectedly, this was followed by an age-dependent increase in mature
BDNF protein. Bdnf mRNA and phospho-TrkB levels remained unaltered in the cortical tissue samples of middle-aged APdE9
mice. Immunohistological studies revealed increased BDNF immunoreactivity around amyloid plaques indicating that the
plaques may sequester BDNF protein and prevent it from activating TrkB. If similar BDNF accumulation happens in human
AD brains, it would suggest that functional BDNF levels in the AD brains are even lower than reported, which could partially
contribute to learning and memory problems of AD patients.
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Introduction
The transgenic APPswe/PS1dE9 (APdE9) mouse line is a widely
used model of Alzheimer’s disease (AD). Specific mutations in
amyloid precursor protein (APP; K595N, K596L) and presenilin-1
(exon 9 deletion) genes in these mice lead to altered proteolytic
processing and metabolism of APP in brain which further lead to
increased production of highly insoluble amyloid-b aggregates.
Consequently, amyloid plaques gradually develop in the cortex
and hippocampus of APdE9 mice starting at 4 months of age [1],
which is followed by memory impairment 4–8 months later [2,3].
Thus, these mice recapitulate the order of pathological events in
AD patients, in whom amyloid plaque formation can progress for
years before memory impairment becomes manifested, as revealed
by recent PET imaging studies with amyloid binding ligand [4,5].
The APdE9 mice therefore offer an excellent model for studying
the molecular mechanisms downstream of the amyloid plaque
formation and subsequent memory impairment.
Neurotrophins (NGF, nerve growth factor; BDNF, brain-
derived neurotrophic factor; NT-3, neurotrophin-3; NT-4, neu-
rotrophin-4) are a small family of secreted trophic proteins that
critically regulate the survival and differentiation of specific
subpopulations of neurons in the peripheral nervous system
during early development [6]. In the adult brain NGF preferen-
tially supports cholinergic neurons located in basal forebrain [7–
9]. On the other hand, the role of BDNF in the regulation of
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synaptogenesis and neuronal plasticity and maintenance in several
brain areas and neuronal subsystems has been well characterized
[6,10,11].
Growing body of evidence suggests that neurotrophin mediated
trophic support is reduced in AD [12]. For example, the levels of
pro-apoptotic form of NGF, pro-NGF, are increased in AD
patients [13]. Moreover, reduced levels of BDNF mRNA and
protein (pro and mature) have been detected in AD patients and in
some animal models of AD [14–23]. However, one study reported
increased BDNF protein levels in AD brains [24].
Previous studies indicating abnormal neurotrophin signaling in
AD together with the known ability of neurotrophins to support
survival of their target neurons after injury has led to a suggestion
that neurotrophins could prevent or delay neuronal and synaptic
loss seen in neurodegenerative disorders, including AD [25].
Indeed, NGF delivery into the brain ameliorates memory
impairment associated with old age [8] and amyloid-b infusion
[26] in rats, and most importantly, clinical AD [27]. Furthermore,
viral transduction or direct infusion of BDNF protein in the
entorhinal cortex has been shown to reverse neuronal atrophy and
synapse loss in an AD mouse model as well as in aged rats and
primates [28]. In line with these observations we have recently
shown that overexpression of the dominant-negative TrkB
receptor, TrkB.T1, in APdE9 mice exacerbated their spatial
memory impairment at 12 months of age while the overexpression
of catalytic TrkB receptors alleviated it [29]. The present study
addressed the next logical question whether a decrease in the main
TrkB ligand, BDNF, would also lead to aggravated spatial
memory impairment in AD model mice, which would further
indicate its role in AD pathology. To this end, we crossed APdE9
mice with BDNF deficient mice (Bdnf+/2), and tested spatial
learning and memory of these mice in the Morris swim task at the
age of 12 months. We also examined the brain BDNF signaling




The APPswe/PS1dE9 (APdE9) founder mice were obtained
from Johns Hopkins University, Baltimore, MD, USA (D. Borchelt
and J. Jankowsky, Dept. Pathology) and a colony was established
at the University of Eastern Finland (Kuopio, Finland). These
mice were generated by co-injection of chimeric mouse/human
APPswe (mouse APP695 harboring a human Ab domain and
mutations K595N and M596L linked to Swedish familial AD
pedigrees) and human PS1-dE9 (deletion of exon 9) vectors
controlled by independent mouse prion protein promoter elements
[30]. This mouse line was originally maintained in a hybrid C3HeJ
6 C57BL6/J F1 background, but the mice used in the present
study were derived from backcrossing to C57BL6/J for 12
generations. The development of Bdnf+/2 heterozygote knock-
out mice (C57BL6/J background) have been described previously
by Ernfors et al [31] (obtained from Jackson Laboratory). Crossing






The housing conditions (National Animal Center, Kuopio,
Finland) were controlled (temperature +22uC, light from 07:00 to
19:00; humidity 50–60%), and fresh food and water were available
ad libitum. All behavioral tests were conducted between 9:00–16:00.
The experiments were conducted according to the Council of
Europe (Directive 86/609) and Finnish guidelines, and approved
by the State Provincial Office of Eastern Finland (animal permit:
ESAVI-10-05581). All experiments were designed and conducted
in manner minimizing the use (e.g. sufficient number of animals
per group) and suffering of animals.
The animals used in the behavioral testing started the tests at
the age of 12 months and were sacrificed at the age of 13 months.
The number of animals in each behavioral test and port mortem
assay is given in Table 1 and Table 2.
Behavioral Testing
Morris swim task (water maze). The Morris swim
navigation task was used to test spatial learning and memory.
The apparatus consisted of a black plastic pool with a diameter of
120 cm and a black escape platform (14 cm614 cm). The pool
was filled with water 1.0 cm above the escape platform and the
temperature of the water was constantly kept at 2060.5uC. The
mice were first pre-trained in two consecutive days to find and
climb onto the submerged platform, aided by a guiding alley (1 m
614 cm625 cm). In the testing phase (days 1–4), five 60-second
trials per day were conducted with a recovery period of 2–5 min in
a warmed cage between the trials. The location of the hidden
platform was kept constant and the starting position varied
between four different locations at the pool edge, with all mice
starting from the same position in a given trial. Each mouse was
placed in the water with its nose pointing towards the wall. If the
mouse failed to find the escape platform within testing period, it
was placed on the platform for 10 s by the experimenter (the same
time was allowed for mice that found the platform). On day 5 the
trial length was reduced to 40 s. In order to test the search bias the
last trial on that day was run without the platform. A computer
connected to an image analyzer (HVS ImageH, Hampton, UK)
Table 1. The number of animals of the APdE96 Bdnf+/2
crossings included in the behavioral tests and post mortem
assays.




AwBw 13 13 13 3
AwB2 16 16 16 3
A+Bw 18 18 16 4




A+Bw 16 5 8
A+B2 17 6 8
Abbreviations for genotypes: AwBw=wt x wt; AwB- =wt x Bdnf+/2;
A+Bw=APdE9 x wt; A+B- =APdE9 x Bdnf+/2. Other abbreviations: BDNF=brain-
derived neurotrophic factor; ELISA = enzyme-linked immunosorbent assay;
HC= hippocampus; WB=western blot.
doi:10.1371/journal.pone.0068722.t001
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calculated the escape latency to find the hidden platform, swim
path length and the swimming speed. For the evaluation of
thigmotaxis behavior the pool was divided into three concentric
zones of equal surface area, and the time spent in the outer zone
was calculated (the platform was located in the middle zone). The
search bias during the probe trial was measured by calculating the
time the mice spent in the vicinity of the former platform position,
defined as target area (centered on the platform, diameter of
30 cm). This target area comprised 6.25% of the total surface area
of the pool. Thus, if a mouse swims randomly in the pool it would
expect to spend 2.5 s in the target area during the 40-second probe
trial.
Spontaneous explorative activity. Spontaneous explorato-
ry activity was analyzed in an observation cage (26626639 cm)
with white opaque walls using infrared photo detection method
coupled with an automated activity monitor (TruScanH, Coul-
bourn Instruments, CO, USA). The system was designed to enable
separate monitoring of horizontal (XY-move time) and vertical
activity (rearing). The test session took 10 min and was replicated
after 48 h to assess the extent of habituation to the test cage. To
avoid odor traces the test cage was cleaned with 70% ethanol
before each mouse.
Rotarod
The Rota-RodH apparatus (Ugo Basile, Comerio, Italy) was
used to test motor coordination and balance. The mouse was
placed on a round rod (2 cm in diameter), the rotation of which
gradually increased from 5 to 30 rpm. The latency to fall off (or
turn two full rounds around with the rod) was recorded up till an
8-min cut-off time. The mouse was adapted to the test by first
giving it 30 s to stay on a stationary rod and additional 30 s with
the minimum speed of rotation.
Biochemical Analysis
At the end of the experiment all female mice (see Table 1) were
deeply anesthetized with pentobarbiturate-chloral hydrate cocktail
(60 mg/kg each) and perfused transcardially with 50 ml heparin-
ized ice-cold 0.9% saline (10 ml/min). The brain was removed
and dissected on ice into the following blocks: frontal, parietal and
temporal cortices, and hippocampus bilaterally. The tissue was
snap frozen in liquid nitrogen and stored at –70uC. Frozen tissue
samples were similarly collected in an additional age series from 3-,
7-, 9-, 13-, and 15-month-old APdE9 and wild-type male or female
mice (see Table 2).
Enzyme-linked immunosorbent assay (ELISA). BDNF
protein levels were assessed using ELISA as previously described
[32,33]. The assay preferentially detects mature BDNF over pro-
BDNF and shows no cross-reactivity with other neurotrophins
[33]. Briefly, brain samples were homogenized in NP++ buffer
(137 mM NaCl, 20 mM Tris, 1% NP-40, 10% glycerol, 48 mM
NaF, 26Complete Inhibitor mix (Sigma-Aldrich, St. Louis, MO)
and 2 mM Na3VO4), incubated on ice for 15 minutes, centrifuged
(16000 g, 15 min, +4uC) and the supernatants were collected.
Next the samples were diluted (1:10-15) in Hanks buffer (125 mM
NaCl, 5 mM KCl, 1.2 mM NaH2PO4, 1 mM CaCl2, 1.2 mM
MgCl2, 1 mM ZnCl2, 10 mM Glucose, 25 mM HEPES, 0.25%
BSA; pH 7.4), acidified (pH 2-3) with 1N HCl and after 15
minutes neutralized with 1N NaOH. BDNF standards, samples
(all 170 ml) and POD-conjugated secondary mouse monoclonal
BDNF antibody (mAb#9, see Ref. 32; 30 ml, 1:1900 in Hanks
containing 6.66% BSA and 0.66% Triton X-100) were transferred
to pre-blocked (Hanks buffer, 2% BSA, 0.1% Triton X-100) Nunc
Maxisorb ELISA (Thermo Fisher Scientific, Vantaa, Finland)
plates that were previously coated with the primary mouse
monoclonal BDNF antibody (mAb#1, see Ref. 32; 1:4000 in
Carbonate buffer, over night, +4uC). Next morning the plates were
extensively washed with PBS-T and the colorimetric reaction was
initiated, terminated and counted according to manufacturer9s
instructions (BM Blue, Roche Diagnostics Oy, Espoo, Finland).
BDNF content was calculated according to the standard curve.
The r2 for the standard curve was $0.98 in all experiments. The
BDNF ELISA assay was further validated by running separate
analyses with hippocampal tissues obtained from conditional
BDNF knock-out mice [34] and hippocampal tissues obtained
from mice chronically treated with fluoxetine [35], an antidepres-
sant drug that has been shown to slowly facilitate BDNF synthesis
Table 2. The number of APdE9 (A+) and wild-type (Aw) animals in the aging study on BDNF and NGF protein and TrkB
phosphorylation levels.
Cortex HC Cortex Cortex Cortex HC
BDNF BDNF NGF BDNF pTrkB pTrkB
ELISA ELISA ELISA PCR WB WB
Aw A+ Aw A+ Aw A+ Aw A+ Aw A+ Aw A+
Female
3 mo 6 5
7 mo 6 7
12 mo 12 12 12 12 8 7 7 9 9–12 10–12 12 12
13 mo 7 6
15 mo 14 13–14 14 14
Male
3 mo 6 6
9 mo 8 9
15 mo 6 6
Abbreviations: BDNF =brain-derived neurotrophic factor; ELISA = enzyme-linked immunosorbent assay; HC= hippocampus; NGF = nerve growth factor;
PCR= polymerase chain reaction; WB=western blot; pTrkB =phosphorylated TrkB.
doi:10.1371/journal.pone.0068722.t002
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in hippocampus [36]. Sets of results were confirmed using a
commercially available BDNF ELISA kit according to manufac-
turer9s instructions (Quantikine human BDNF ELISA kit, R&D
systems, Minneapolis, MN, USA).
Western blotting. For BDNF western blotting an equal
volume of protein was mixed with 26Laemmli buffer, heated and
run in SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel
electrophoresis), under reducing conditions and transferred to a
PVDF (polyvinylidene fluoride) membrane (Hybond-P, GE
Healthcare, Buckinghamshire, UK). The membrane was blocked
with 3% non-fat dry milk and incubated with a polyclonal BDNF
antibody raised against the mature BDNF protein (1:500, Catalog
number sc-546, Santa Cruz Biotechnology, CA, USA). This
antibody readily recognizes both pro and mature forms of BDNF
and has been extensively used for the detection of BDNF in
western blotting. The specificity of this antibody to recognize
BDNF in western blotting was confirmed by employing hippo-
campal tissue lysates from cleavage-resistant BDNF knock-in mice
(M. Kojima, personal communication), conditional BDNF knock-
out mice [34,37] and mice chronically treated with fluoxetine [35],
as controls. After washing, the specifically bound antibodies were
detected using HRP-conjugated anti-rabbit antibody and electro-
chemiluminescence (ECL) -based detection. For normalization
Tuj1 (-tubulin) immunodetection was performed after membrane
stripping (1:1000, Babco, Richmond, CA, USA). Band intensity
was analyzed using ImageJ software (NIH, Bethesda, MD, USA).
For TrkB receptor tyrosine phosphorylation analysis an equal
amount of protein was incubated with wheat germ agglutinin
agarose (Catalog number A-2101-25, EY laboratories, San Mateo,
CA, USA) for 1.5 hours at +4C. Next the beads were washed with
NP++ buffer, specifically bound proteins eluted with 26Laemmli
buffer, separated in SDS-PAGE and transferred to PVDF
membrane. After blocking the membrane was incubated with a
polyclonal phospho-TrkBY816 antibody raised in rabbits (1:1000; a
kind gift from Dr. Moses Chao, Skirball Institute, New York,
USA). The generation and validation of this antibody has been
characterized in previous publications [38–40]. After washing
specifically bound antibodies were detected using HRP-conjugated
anti-rabbit antibody and ECL -based detection. For normalization
TrkB immunodetection (1:1000, Catalog number 610101, BD
Transduction Laboratories, Franklin Lakes, NJ, USA) was
performed after membrane stripping. Band intensity was analyzed
using ImageJ software.
Reverse transcription polymerase chain reaction (RT-
PCR). The level of total Bdnf mRNA was analyzed using RT-
PCR as described in Karpova et al [41]. Briefly, after Trizol –
based RNA extraction (Invitrogen, Carlsbad, CA, USA), total
RNA was treated with DNAse I mix (Fermentas GmbH, Helsinki,
Finland) and then reverse transcribed using oligo(dT) primer and
SuperScript III Reverse Transcriptase mix (Invitrogen, Carlsbad,
CA, USA). The control reactions without Reverse Transcriptase
were also performed. The amount of cDNA was quantified using
LightCycler SYBR-Green 1 Master mix (Roche Diagnostics Oy,
Espoo, Finland) by real-time PCR. Total Bdnf cDNA was
amplified using the following primers: 59-GAAGGCTG-
CAGGGGCATAGACAAA-39 and 59-TACACAG-
GAAGTGTCTATCCTTATG-39. For normalization, GAPDH
cDNA levels were analyzed with the following primers 59-
GGTGAAGGTCGGTGTGAACGG-39 and 59-CATGTAGTT-
GAGGTCAATGAAGGG-39. Ct values from each sample were
obtained using the LightCycler 480 software (Roche Diagnostics
Oy, Espoo, Finland).
Histological Analysis
At the end of the experiment all male mice (see Table 1) were
deeply anesthetized with pentobarbiturate-chloral hydrate cocktail
(60 mg/kg each) and perfused transcardially with 50 ml heparin-
ized ice-cold 0.9% saline (10 ml/min) followed by 4% parafor-
maldehyde. Brains were transferred to a 30% sucrose solution
overnight and finally stored in a cryoprotectant in 220uC for later
immunohistology. The brains were cut on a sliding/freezing
microtome into 35 mm coronal sections. All sections were
pretreated with sodium citrate solution at 80uC for 30 min.
To visualize the location of the strongest BDNF immunoposi-
tivity two sections at the level of mid-hippocampus were stained
with the same specific BDNF antibody that was used as primary
capturing antibody for ELISA assays (1:1000, mAb#1). This
antibody has been raised against mature BDNF and therefore
cannot differentiate mature and pro forms of BDNF [32].
Importantly, this antibody does not recognize other members of
neurotrophin family [32]. The sections were pretreated with 0.3%
H2O2 in TBS-T for 30 min and then blocked in 1.5% normal goat
serum in TBS-T for 1 h. The sections were incubated with the
primary antibody overnight at room temperature on a shaker
table. Following incubation, the sections were rinsed thoroughly
with TBS-T and transferred to the solution containing the
secondary antibody, biotinylated goat–anti mouse 1:1500 (Catalog
number BA-9200, Vector Laboratories, Peterborough, UK). After
2 hours of incubation the sections were rinsed three times and
transferred to a solution containing Streptavidin 1:1000 (GE
Healthcare, Buckinghamshire, UK) for 2 hours. Visualization of
BDNF-immunoreactivity was achieved by incubation with DAB–
Ni solution. Stained sections were mounted on gelatin-coated
slides and dehydrated in alcohol series, cleared with xylene and
mounted in Depex.
To visualize amyloid plaque every 6th section in 5 A+Bw and 6
A+B- mice was stained with monoclonal mouse anti-human
antibody W0-2 (Ab4–10, 1:30000, Genetics, Schlieren, Switzer-
land). The sections were incubated overnight at room temperature
on a shaker table. Following incubation, the sections were rinsed
thoroughly with TBS-T and transferred to a solution containing
the secondary antibody, biotinylated goat–anti mouse (1:1500;
Vector Laboratories, Peterborough, UK). After 2 hours of
incubation the sections were rinsed three times and transferred
to a solution containing Streptavidin (1:1000; GE Healthcare,
Buckinghamshire, UK) for another 2 hours. Visualization of Ab
plaques was achieved by incubation with DAB–Ni solution.
Stained sections were mounted on gelatin-coated slides and
dehydrated in alcohol series, cleared with xylene and mounted
in Depex.
To visualize dystrophic neurites around amyloid plaques with
hyperphosphorylated tau we stained three frontal sections in 8
A+Bw and 8 A+B- mice with monoclonal anti-human PHF-Tau
(AT8; 1:1000, Thermo Scientific, Rockford, IL, USA). After
citrate solution pretreatment, sections were blocked in 3% bovine
serum albumin in TBS-T for 60 min. The primary antibody was
also diluted into 3% BSA in TBS-T. The sections were incubated
overnight at 4uC on a shaker table. Following incubation, the
sections were rinsed thoroughly with TBS-T and transferred to the
solution containing the secondary antibody, biotinylated goat–anti
mouse (1:1500; Vector Laboratories, Peterborough, UK). After 2
hours of incubation the sections were rinsed three times and
transferred to a solution containing Streptavidin (1:1000; GE
Healthcare, Buckinghamshire, UK) for 2 hours. Visualization of
antibody positivity was achieved by incubating the sections for 2
hours at room temperature in a solution containing CY3 red
fluorescent dye (1:1000; TSA- Plus Cyanine 3 System kit,
Bdnf Gene Deficiency and APdE9 Mice
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PerkinElmer, Waltham, MA, USA). Stained sections were
mounted on gelatin-coated slides and mounted in Vectashield
(Vector Laboratories, Peterborough, UK).
For quantification of amyloid plaque load, three sections with
210 mm intervals were selected from the septal (rostral) half of the
hippocampus. The sections were photographed using the Olym-
pus BX40 microscope (Tokyo, Japan) with DP50 camera attached
and images were treated and analyzed using Photoshop CS3
program (Adobe Systems Inc., San Jose, CA, USA). The images
were transformed to grayscale and their brightness and contrast
were changed using the shadow-highlight command (1 time for
TK, maintaining the same threshold for all subgroups in a series).
The area of the hippocampus was measured using the lasso-tool
and hippocampal amyloid plaques were measured using the color
range command (using threshold 110). The final value was
obtained by dividing the amyloid plaque area by the total
hippocampal area.
Because AT8-positive terminals were restricted to the immedi-
ate vicinity of amyloid plaques, we calculated their surface area
relative to the plaque size. First, we identified the most posterior
frontal section where corpus callosum splits (,bregma +1.2) and
selected those 15 amyloid plaques in the anterior cingulate cortex
in each hemisphere that were closest to the midline. Based on the
characteristic shape in the background (green) fluorescence we
could identify the plaques and calculate their combined surface
area. The total AT8-positive surface area (red fluorescence) was
then calculated on the focal plane that gave the highest total area
for each plaque. The total AT8-positive area was divided by the
total plaque area and expressed as %.
As a control for nonspecific binding, amyloid plaques were also
stained for anti-NGF, anti-CDNF antibodies, as well as for anti-
GFAP to visualize activated astrocytes. We stained the section
overnight using polyclonal rabbit anti-NGF (Santa Cruz, Dallas,
TX, USA, cat.no SC-549) at 1:2000 as the primary antibody.
Goat anti-rabbit IgG biotinylated (Vector Laboratories, Peterbor-
ough, UK, cat.no BA-1000) at 1:500 was used as the secondary
antibody and streptavidin (GE Healthcare, Buckinghamshire, UK)
at 1:1000 as the tertiary antibody, both incubated for 2 h in TBS-
T. Rabbit polyclonal antibody [42] was used for CDNF at 1:1000
with an overnight incubation. The secondary and tertiary
antibodies were the same as for NGF staining. Activated astrocytes
were visualized by monoclonal anti-GFAP (clone G-A-5, Sigma-
Aldrich, St. Louis, MO, USA, cat.no. G3893) at 1:1000 with
overnight incubation. Goat anti-mouse HRP (Pierce, Rockford,
IL, USA, cat.no. 31430) at 1:500 was used as the secondary
antibody with a 2-h incubation. For all stainings, the pretreatment
was as above: first 0.3% H2O2 in TBS-T for 30 min, then blocking
in 1.5% normal goat serum in TBS-T for 1 h and visualization
with DAB-NI solution.
Statistical Analysis
The statistical analysis of behavioral tests was done using SPSS
for Windows 14.0 software. The normal distribution of values for
selected parameters in separate groups was tested using Kolmo-
gorov-Smirnov Z one-sample test. The main means of analysis was
two-way ANOVA with APdE9 (A+ vs. Aw) and Bdnf+/2 (B- vs. Bw)
as between subject factors. When several time points were
included as a within-subject factor, ANOVA for repeated
measures was used with the same A and B factors. Males and
females were always analyzed separately unless otherwise stated.
However, in cases of borderline significance, we also assessed the
effects with males and females combined. To assess the influence
of body weight on sensible the behavioral test parameters, we ran
the ANOVAs also with the body weight as a covariant. Post hoc
analyses were done using Dunnett’s test with the AwBw groups as
the reference. In cases where we focused on the effect of Bdnf
deficiency alone, Bdnf+/2 mice (B-) were compared to Bw mice of
the corresponding APdE9 gene status using Student’s t-test. The
statistical analysis of biochemical tests were performed with Two-
way Student’s t-test (comparison of two groups) or with One-way
or Two-way ANOVA followed by Tukey-Kramer post hoc test.
Statistical significance was set at p,0.05.
Results
Bdnf Gene Deficiency Leads to Increased Body Weight
As described in earlier studies [43], we found significantly
increased body weight of Bdnf+/2 mice when compared to wild-
type mice in both genders (males: F1,61 = 15.7, p,0.001; females:
F1,58 = 13.5, p= 0.001). The body weights at the end of the study
among the males were as follows (in grams; mean6SEM): AwBw
34.560.9, AwB2 38.861.6, A+Bw 34.160.8, A+B2 39.261.2,
and among the females follows: AwBw 27.260.6, AwB2
30.361.0, A+Bw 26.360.5, A+B2 29.160.9. The group sizes
and labels are explained in Table 1. To take into account the
possible confounding effect of body weight, we systematically
replicated the statistics of the behavioral tests with the body weight
as a covariant.
Impact of Bdnf Gene Deficiency on Spatial Learning and
Memory in Aged APdE9 Mice
We crossed APdE9mice with Bdnf+/2mice and tested the spatial
learning and memory of each resulting genotype in the Morris
swim task at the age of 12 months. This age was selected based on
our recent finding demonstrating that the over-expression of
dominant-negative truncated TrkB receptor aggravates memory
impairment in 12-month-old APdE9 mice [29].
As shown by numerous studies on aged APdE9 transgenic mice
before, both APdE9 transgenic males (F1,61 = 17.2, p= 0.0001) and
females (F1,59 = 4.7, p = 0.03) had longer escape latencies to the
hidden platform when compared to corresponding wild-type mice.
Importantly, Bdnf gene deficiency further strongly impaired
learning in males (p = 0.007) and showed a similar trend in
females (p = 0.07). However, among males, but not females, Bdnf
gene deficiency on its own also reduced swimming speed (p= 0.02)
that could partially contribute to significantly increased escape
latency in males in this task. Reduced swimming speed in turn
likely stemmed from obesity that rendered the mice more tolerant
to cool water and more prone to float. Indeed, when body weight
was included in the ANOVA model as a covariant, the impact of
Bdnf gene deficiency on swimming speed in male mice also
disappeared (p = 0.16). However, even when the influence of body
weight was taken into account in the statistical model, male Bdnf+/
2 mice displayed longer escape latencies than those carrying both
Bdnf alleles (p = 0.01). Furthermore, the Bdnf effect could be
observed in both APdE9 transgenic and wild-type mice (no
interaction between the genotypes, all p values .0.51). To further
analyze task acquisition with little confounding effect of swimming
speed, we assessed the swim path lengths of mice (Fig. 1 A-B).
Similarly to escape latency, swim path length revealed impaired
learning among APdE9 mice (males: F1,61 = 12.9, p= 0.001;
females: F1,59 = 4.7, p = 0.03). Both male and female Bdnf
+/2
showed a trend toward increased path length (p = 0.07, for both
genders). However, when both sexes were combined, the effect of
Bdnf gene deficiency became clearly significant (F1,124 = 7.2,
p = 0.008; Fig. S1A). In addition, when the body weight was
included in the ANOVA model, the effect of Bdnf gene deficiency
was significant in both males (p = 0.01) and females (p = 0.04).
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Furthermore, in the post hoc tests, among for sexes only the double
mutant APdE9 6 Bdnf+/2 mice differed significantly from the
double wild-type controls (Fig. 1 A–B). There was no interaction
between the genotypes in the swim path length in either sex or in
the pooled analysis (all p-values .0.57).
Successful performance in the Morris water maze requires that
the animals abandon their natural but fruitless effort to search for
an escape in the pool wall. This thigmotaxic behavior was
significantly influenced by the APdE9 mutations in males
(F1,61 = 15.7, p = 0.0002; Fig. 1C) and females (p = 0.0001,
F1,59 = 16.8; Fig. 1D). Bdnf
+/2 males also displayed strong
Figure 1. Bdnf gene deficiency aggravates memory impairment of APdE9 mice in the Morris swim task. (A) Swim path length to the
hidden platform in males; ** significant APdE9 gene main effect (p = 0.002, ANOVA-rm), ## A+B2 mice differ significantly from the AwBw control
group (p = 0.001, Dunnett’s post-hoc test). (B) Same in females; # A+B- mice differ significantly from the AwBw control group (p = 0.02, Dunnett’s
post-hoc test). (C) Thigmotaxis calculated as percent time spent in the wall zone in males; *** significant APdE9 gene main effect (p = 0.0002, ANOVA-
rm), 111 Bdnf gene main effect (p = 0.0003, ANOVA-rm), ### A+B2 mice differ significantly from the AwBw control group (p,0.001, Dunnett’s post-
hoc test). (D) Same in females; *** significant APdE9 gene main effect (p = 0.0001, ANOVA-rm), ## A+B2mice (p = 0.001) and # A+Bw mice (p = 0.03)
differ significantly from the AwBw control group (Dunnett’s post-hoc test). The dashed line indicates a random performance. (E) Search bias (time in
the target area in seconds) in the probe test without the platform on day 5 in males; ** significant APdE9 gene effect (p = 0.007, ANOVA). (F) Same in
females. Abbreviations for genotypes: AwBw=wt x wt; AwB2=wt x Bdnf+/2; A+Bw=APdE9 x wt; A+B- =APdE9 x Bdnf+/2.
doi:10.1371/journal.pone.0068722.g001
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thigmotaxis (p = 0.0003; Fig. 1C) compared to mice with both
Bdnf alleles, but this tendency was non-significant among females
(p = 0.19; Fig. 1D). When both sexes were combined, the Bdnf
main effect was significant (F1,124 = 13.8, p,0.001; Fig. S1B).
Notably, among both males and females, mice carrying both
APdE9 and Bdnf mutations seemed to have the strongest
thigmotaxis (Fig. 1C–D).
Memory of the platform location was tested on the last day with
a probe trial without the platform and assaying the search bias of
the mice. Among males, APdE9 mutant mice showed clearly
impaired search near the former platform location (p = 0.007;
Fig. 1E), while such genotype difference was not present among
females (p = 0.58; Fig. 1F). In contrast to task acquisition, memory
for the platform location was not dependent on the Bdnf gene
status (males: p = 0.53; females: p = 0.36).
Bdnf Gene Deficiency Normalizes the Hyperactivity of
APdE9 Mice in a Novel Environment
Our recent study showed that genetic inhibition of the TrkB
receptor counteracts the hyperactivity present in APdE9 mice [29].
Therefore, we assessed spontaneous exploration activity in a novel
environment using a similar protocol and the same test cage as in
our previous study [29]. As illustrated in Fig. 2, APdE9 mutant
mice traversed a longer distance during the 10-min test than wild-
type mice. This was true for males (F1,30 = 7.4, p= 0.01; Fig. 2A)
and females (F1,28 = 5.2, p = 0.03; Fig. 2B). This hyperactivity was
lost in the double mutant APdE96 Bdnf+/2 mice, both in males
(F1,31 = 0.0, p = 0.99; Fig. 2A) and in females (F1,30 = 0.08,
p = 0.78; Fig. 2B). The behavior of Bdnf+/2 mice without APdE9
mutations resembled the behavior of wild-type mice. The findings
were only slightly changed when taking the body weight into
account in the ANOVA model. The APdE9 effect remained
significant in the Bdnf wild-types males (p = 0.008) and was of
borderline significance in females (p = 0.05). Furthermore, the
APdE9 effect was lost in the double mutant APdE9 x Bdnf+/2 mice
(males, p = 0.95; females, p = 0.94). When the mice were subjected
to the test two days later no differences were observed between the
groups, thus demonstrating equal habituation to the testing
environment in all genotypes.
Bdnf Gene Deficiency Improves Motor Coordination in
APdE9 Mice
To further assess possible genotype differences in motor
coordination and balance, we tested the ability of mice to stay
on an accelerating rotating rod (Rotarod). Among male mice, Bdnf
deficiently did not affect time on the rod (Fig. 2C), whereas
among females there was a significant main effect of Bdnf
(F1,58 = 5.9, p= 0.02) as well as a marginal APdE9 x Bdnf
interaction (p= 0.05). However, the difference was such that
female APdE9 x Bdnf+/2 double mutant mice surprisingly
outperformed the other groups in this task (Fig. 2D). In addition,
when the body weight was taken into account in the ANOVA
model, a significant Bdnf effect emerged in both sexes (both,
p = 0.04). The APdE9 x Bdnf interaction remained marginally
significant in females (p = 0.05), but did not reach significance in
males (p = 0.08). These observations clearly indicate that loss of
hyperactivity in APdE9 x Bdnf+/2 mice does not simply reflect
difficulty to move around.
Bdnf Gene Deficiency does not Alter Amyloid Pathology
in APdE9 Mice
Next we analyzed the effect of Bdnf deficiency on amyloid
pathology in APdE9 mice. This analysis was done in male mice
only. There was no difference between Bdnf+/2 and Bdnf+/+
carriers in the hippocampal amyloid load (t9 = 0.49, p = 0.64;
Fig. 3C). Amyloid plaques in APdE9 mice were surrounded by
dystrophic neurites that stained positively for hyperphosphorylated
tau (as revealed by AT8 antibody; Fig. 3 A, B). The AT8-positive
area around cortical plaques in the anterior cingulate cortex was
not significantly different between APdE9 x Bdnf+/2 and APdE9 x
Bdnf+/+ mice (t14 = 1.3, p = 0.22; Fig. 3D).
Mature BDNF Protein Levels are Increased in Aged APdE9
Mouse Brain
Both reduced and increased bdnf mRNA and BDNF protein
levels have been reported in different animal models of AD
[23,44,45]. Thus, we sought to examine the regulation of BDNF
signaling in APdE9 mice during different stages of pathology. To
this end we analyzed brain tissue of APdE9 mice and wild-type
littermates that were not part of the behavioral study. The ages,
gender and number of animals are summarized in Table 2. We
first determined brain BDNF protein levels using an ELISA assay
in female APdE9 mice at the age of 12 months, when memory
impairment begins to manifest in these mice [3]. In agreement
with some previous findings [45], BDNF protein levels were not
reduced but slightly increased in the hippocampus of female
APdE9 mice (Fig. 4A). Interestingly, even more pronounced
BDNF protein increases were observed in several cortical areas
(Fig. 4A). Indeed, the increases in BDNF protein level were
significantly higher in frontal cortex, parietal cortex and temporal
cortex compared to hippocampus (all p values ,0.005). Brain
BDNF levels in female APdE9 mice continued to increase toward
15 months age to the same extent in all brain areas studied
(Fig. 4B), reaching over two-fold levels compared to WT mice in
the temporal cortex. This increase in cortical samples seemed to be
selective for BDNF, since temporal cortex samples of aged APdE9
mice revealed no significant changes in NGF protein levels
compared to WT littermates (Fig. 4C). Unexpectedly, the levels of
total Bdnf mRNA in the cortical samples were not significantly
different between middle-aged WT and APdE9 mice (Fig. 4D).
To investigate the relationship between the observed increase in
BDNF levels and amyloid accumulation in the APdE9 mice, we
examined BDNF protein levels with ELISA in temporal cortical
samples of APdE9 mice before the appearance of plaques. At the
age of 3 months female APdE9 mice showed a statistically
significant reduction in BDNF levels and no significant differences
were seen in males (Fig. 4E–F). At the age of 7 months, BDNF
protein levels were not different from the wild-types in female
APdE9 mice, while at the age of 9 months, BDNF protein levels
were significantly increased in male APdE9 mice (Fig. 4E–F). This
was followed by gradual and age-dependent increase in BDNF
protein levels in the temporal cortex of APdE9 mice in both sexes.
Next we assessed BDNF protein levels in female 13-month-old
double mutant (APdE9 x Bdnf+/2) mice that have been previously
subjected to behavioral tests. As expected, Bdnf+/2 mice showed
approximately 50% down-regulation of BDNF protein in the
temporal cortex and hippocampus (Fig. 5A–B). Again, as revealed
by ELISA, BDNF protein levels in APdE9 mice were increased
substantially in the temporal cortex and moderately in the
hippocampus. Similarly, the levels of BDNF protein in the
hippocampus and temporal cortex were increased to the same
extent also in APdE9 x Bdnf+/2 mice compared to wt x Bdnf+/2
mice, reaching the wild-type level in the temporal cortex (Fig. 5A–
B). Table 3 summarizes the correlations between individual brain
BDNF levels and the key behavioral testing parameters. The only
significant correlation was between BDNF levels in the temporal
cortex and thigmotaxis, such that high BDNF levels were
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associated with strong tendency to keep swimming near the pool
wall.
The ELISA method that we used for BDNF protein analysis
preferentially detects mature-BDNF over pro-BDNF [33]. To
confirm the ELISA experiments and to examine the potential
changes of pro-BDNF levels in the brains of APdE9 mice, we
performed western blot analyses with an antibody that was
confirmed to detect both mature and pro forms of BDNF in brain
tissue samples (Fig. S2). In agreement with ELISA data, western
blot analysis showed that the levels of mature BDNF were strongly
increased in the temporal cortex of aged APdE9 mice and APdE9 x
Bdnf+/2 mice when compared to WT or Bdnf+/2 mice, respectively
(Fig. 6). The protein levels of pro-BDNF were extremely low or
undetectable in all of the samples obtained from WT or mutant
mice carrying APdE9 and/or Bdnf mutations.
Next, we tested if the relatively robust increase in the levels of
mature BDNF protein in the cortex of aged APdE9 mice leads to
functional changes in TrkB receptor activity. However, the TrkB
phosphorylation status remained unaltered in the hippocampal
and cortical samples of 12-month-old APdE9 mice (Y816, Fig. 7;
Y705/6, data not shown).
BDNF Protein Levels are Predominantly Increased around
Amyloid Plaques in the Brains of Aged APdE9 Mice
Since a robust BDNF up-regulation in the cortex of aged APdE9
mice was not associated with increased levels of Bdnf mRNA and
enhanced TrkB signaling, it is unlikely that the increased BDNF
protein resulted from increased BDNF synthesis. Rather BDNF
might have accumulated into compartments where it could not be
released to activate TrkB. Indeed, when we analyzed the
immunohistochemical localization of BDNF in the brains of
APdE9 and WT mice, strong anti-BDNF immunoreactivity
surrounded amyloid plaques in the hippocampus and cortex of
APdE9 mice in a ‘‘doughnut-like’’ fashion (Fig. 8A–C). In the
absence of amyloid plaques such ‘‘doughnut-like’’ BDNF immu-
noreactivity could not be detected in WT mice (Fig. 8D).
Furthermore, stainings for other neurotrophins (NGF and CDNF)
or activated astroglia resulted in a very different staining pattern,
ruling out the possibility that this is simply a results of nonspecific
binding of antibodies to sticky amyloid plaques (Fig. 8 E–H).
Discussion
We addressed the role of BDNF in Alzheimer’s disease (AD) by
investigating behavior and neurochemistry in double mutant mice
generated by crossing BDNF-deficient (Bdnf+/2) mice with an AD
Figure 2. Bdnf gene deficiency normalizes the hyperactivity/hyperexploration of APdE9mice. Distance traversed (cm) in a novel test cage
during 10 min on day 1 and day 3 (habituation) in males (A) and in females (B). * Significant APdE9 gene effect among Bdnf wild-type mice, (p,0.05,
ANOVA-rm). Bdnf gene deficiency does not impair motor coordination and balance despite obesity. Time on the accelerating rotarod in males (C) and
in females (D). * Significant main effect of the Bdnf gene deficiency (p = 0.02, ANOVA). Abbreviations for genotypes: AwBw=wt x wt; AwB2=wt x
Bdnf+/2; A+Bw=APdE9 x wt; A+B2=APdE9 x Bdnf+/2.
doi:10.1371/journal.pone.0068722.g002
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Figure 3. Bdnf gene deficiency does not alter amyloid pathology in APdE9 mice. A) Example of an amyloid plaque (green) in the
hippocampus surrounded by phosho-tau positive dystrophic neurites (red) in an APdE9 mouse carrying both Bdnf alleles (A+Bw). Scale bar = 20 mm.
B) Same in a mouse with only one Bdnf allele (A+B2). C) Amyloid load in the hippocampus expressed as % of examined surface area in APdE9 mice
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mouse model, APdE9 mice. We have previously reported that
inhibition of TrkB signaling aggravates memory impairment in
APdE9 mice, whereas increasing TrkB signaling ameliorates it
[29]. In line with these findings, haploinsufficiency of Bdnf further
exacerbated impaired spatial learning ability of APdE9 mice. This
deficit was most prominent in males. Similarly to APdE9 mice,
Bdnf+/2 males displayed strong wall-hugging behavior (thigmo-
taxis) in the Morris swim task. However, in contrast to the task
acquisition, Bdnf+/2 gene deficiency in APdE9 mice did not
influence their memory for the platform location in the probe test.
One limitation of the present Bdnf+/2 mouse model is the
constitutive nature of the BDNF haploinsufficiency. Among other
things, this led to significant obesity in Bdnf+/2 mice as reported
before [43]. Obesity was a likely confounding factor for escape
latency in the Morris swim task (via decreased swimming speed),
spontaneous exploratory activity and Rotarod performance
among the male mice that showed the largest differences in body
weight due to Bdnf gene deficiency. To circumvent the contribu-
tion of obesity to observed spatial learning deficit in Bdnf+/2 mice,
we took body weight as a cofactor in the statistical model when
assessing escape latency. This approach abolished the Bdnf+/2
associated difference in the swimming speed, but did not abate the
difference in escape latency. In addition, we also analyzed the
swim path length that is less susceptible to the confounding
influence of swimming speed than the more common measure of
escape latency for the task acquisition. This analysis separately for
each sex showed a trend toward impairment in Bdnf+/2 mice,
while in the pooled analysis with both sexes resulted in a clearly
significant Bdnf gene effect. These findings together with a highly
significant increase in thigmotaxis among Bdnf+/2 male mice
strongly suggest that Bdnf+/2 mice were impaired in the Morris
swim task acquisition independent of obesity and decreased
swimming speed associated with the Bdnf+/2 genotype. However,
for some reason the Bdnf gene deficiency no longer manifested as
impairment during the probe task.
In a novel test cage, Bdnf+/2 mutant mice did not differ from
wild-type mice, whereas APdE9 mice showed prominent hyperac-
tivity, as shown before [29]. This hyperactivity was completely
normalized by Bdnf gene deficiency. Again, this finding persisted
even after the possible confounding effect of body weight was
taken into account in the statistical model. Therefore, even if
deficient BDNF signaling is predominantly associated with
deleterious effects it can produce paradoxically beneficial effects
in some specific neuronal systems and behaviors. This notion is
carrying two Bdnf alleles (A+Bw) or only one (A+B2) allele. D) Phospho-Tau positive surface area around amyloid plaques in the anterior cingulate
cortex (expresses as % of the combined plaque surface area) of APdE9 mice carrying two (A+Bw) or one (A+B2) Bdnf alleles.
doi:10.1371/journal.pone.0068722.g003
Figure 4. Age-dependent increase of BDNF protein in the brains of APdE9 mice. A) BDNF protein levels (measured with ELISA) in the
hippocampus, frontal cortex, parietal cortex and temporal cortex of 12-month-old female APdE9 mice. B) BDNF protein levels (measured with ELISA)
in the hippocampus, frontal cortex, parietal cortex and temporal cortex of 15-month-old female APdE9 mice. C) NGF protein levels (measured with
ELISA) in the temporal cortex of 12-month-old female APdE9 mice. D) Total Bdnf mRNA (measured with RT-PCR) in temporal cortex of 12-month-old
female APdE9mice. E) Age-dependent BDNF protein levels (measured with ELISA) in the temporal cortex of wild-type and APdE9 female mice. F) Age-
dependent BDNF protein levels (measured with ELISA) in the temporal cortex of wild-type and APdE9 male mice. A t-test was performed between
wild-type and mutant animals; *p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0068722.g004
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further strengthened by our recent studies demonstrating that
genetic inhibition of the TrkB signaling and bdnf gene deficiency
counteracts the hyperactivity present in APdE9 and Fmr12/2
mutant mice, respectively [29,46]. Finally, male Bdnf+/2 mice
were no worse than other test groups in the Rotarod test despite
prominent obesity, while female double mutant mice outper-
formed other genotypes.
BDNF protein and mRNA levels have been extensively studied
in post-mortem brain tissues obtained from AD patients and in
diverse animal models of AD [12]. Most of these data are favoring
overall reduced BDNF synthesis in AD [17,21,22,47], that is
thought to arise from direct effects of amyloid-b (Ab) on Bdnf
synthesis [48]. In particular, high Ab42/Ab40 ratio and the
formation of large SDS-stable Ab oligomers in brain have been
recently associated with more robust reduction of Bdnf synthesis in
mouse models of AD [23]. Interestingly however, some experi-
ments have reported paradoxical increase of BDNF (mRNA,
protein) in the brains of amyloid plaque forming mice [44,45]. The
observed BDNF increase in these mice appears to be concentrated
predominantly in reactive glial cells around amyloid-b plaques
[44]. Indeed, one human report shows an increased BDNF
immunoreactivity in senile plaques in post-mortem AD patients
[49]. In line with these findings, we observed that BDNF protein
levels were either down-regulated (female) or unaltered (male) in
the cortex of APdE9 mice before the onset of amyloid plaque
formation (3 months). This was followed by an age-dependent
increase in BDNF protein levels in several cortical areas in male
and female APdE9 mice. Our western blot analyses confirmed the
ELISA experiments demonstrating increased levels of mature-
BDNF protein in the neocortex of middle-aged APdE9 mice, while
the levels of pro-BDNF remained undetectable in the cortex in
both APdE9 and WT mice. We were unable to reproduce Bdnf
mRNA induction in the cortical samples of APdE9 mice as has
previously shown by Burbach et al [44], but this may be due to the
fact that we did not microdissect plaques specifically for the
analysis as done in their study. In line with Szapacs et al [45] we
saw an up-regulation of BDNF in the hippocampus of aged APdE9
mice but this increase was significantly less than that seen in the
cortex, consistent with more prominent amyloid load in cortical
regions than in the hippocampus in this mouse model. Further-
more, in agreement with a previous report [44], significant BDNF
immunoreactivity was predominantly seen around amyloid
plaques in APdE9 mice.
As hypothesized before, the observed up-regulation of BDNF
synthesis around amyloid plaques of aged APdE9 mice may be an
attempt to provide neurotrophic support for degenerating neurons
around the plaques [44,49]. Alternatively, BDNF may get
‘‘trapped’’ in the amyloid plaques and escape degradation.
Therefore, we examined whether this BDNF protein induction
would lead to significant changes in TrkB receptor activation by
analyzing the phosphorylation status of TrkB. However, TrkB
phosphorylation at sites Y705/6 and Y816, both of which are
readily activated by BDNF [6], remained unaltered in the cortical
samples of aged APdE9 mice that demonstrated almost 2-fold
increase in mature-BDNF protein levels. Since BDNF through its
Figure 5. Impact of Bdnf gene deficiency on BDNF induction in
13-month-old female APdE9mouse cortex. A) BDNF protein levels
in the temporal cortex of wild-type mice and mice carrying APdE9 and/
or Bdnf+/2 mutations. B) BDNF protein levels in the hippocampus of
wild-type mice and mice carrying APdE9 and/or Bdnf+/2 mutations.
Two-Way ANOVA followed with Tukey-Kramer post hoc test was
performed for statistical analysis. *p,0.05, ***p,0.001 compared to
the respective wt, ###p,0.001 compared to wt/wt.
doi:10.1371/journal.pone.0068722.g005
Table 3. Correlation between hippocampal (HC) and cortical (Ctx) BDNF protein levels and key behavioral test parameters in 13-
month-old female mice.
Ambulatory distance Rod time Mean esc. latency Mean path length Mean wall zone time Search bias
HC BDNF 0.14 20.18 0.21 0.14 0.18 0.21
Ctx BDNF 0.25 20.12 0.29 0.16 0.45* 0.02
All four genotypes are pooled, with n= 29-31 in all correlations. Values are Spearman rho correlation coefficients.
*p = 0.01, p.0.10 for all other correlations.
doi:10.1371/journal.pone.0068722.t003
Figure 6. Mature BDNF protein levels are specifically increased
in 13 month-old female APdE9 mouse cortex. Western blot
analysis of mature-BDNF protein levels in the cortex of wild-type mice
and mice carrying APdE9 and/or Bdnf+/2 mutations. Two-Way ANOVA
followed with Tukey-Kramer post hoc test was performed for statistical
analysis. *p,0.05, ***p,0.001 compared to the respective wt,
###p,0.001 compared to wt/wt.
doi:10.1371/journal.pone.0068722.g006
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TrkB receptor activates the phosphoinositol kinase 3– Akt kinase
pathway, leading to a disinhibition of the most important tau
kinase, glycogen synthase kinase 3b, we also assessed eventual
changes in tau phosphorylation status in amyloid plaques using the
AT8 antibody. This analysis did not show any significant change
in tau phosphorylation, a finding also supported by recently
published report by Castello et al [50]. These findings, collectively
with the lack of concomitant increase in Bdnf mRNA levels,
strongly suggest that a substantial part of BDNF around the
amyloid plaques does not actively participate in signaling. This
would also explain why an ostensible ‘‘normalization’’ of brain
BDNF levels in APdE9 x Bdnf+/2 mice impaired their spatial
learning ability in a way that is consistent with BDNF deficiency.
In other words, Bdnf+/2 genotype was associated with impaired
spatial learning both in mice wild-type for the APdE9 transgene
with half of the total cortical BDNF levels and in APdE9 mice with
similar total cortical BDNF levels as double wild-type mice.
In conclusion, our results are compatible with the idea that
reduced levels of functional BDNF through haploinsufficiency is
deleterious for learning and memory. Our results also support
some of the previous findings suggesting that BDNF may get stuck
into amyloid plaques, which can explain the paradox that APdE9 x
Bdnf+/2 mice with their BDNF levels within the ‘‘normal range’’
are similarly impaired in comparison with their Bdnf wild-type
littermates as mice without the APdE9 transgene. However, further
studies are needed to confirm that BDNF is truly enriched in
detergent resistant brain tissue fractions where the plaques are also
observed. If such accumulation of BDNF would also happen in
human AD brains, it would suggest that functional BDNF levels in
the AD brains are even lower than the already compromised total
BDNF protein or mRNA levels would indicate.
Figure 7. BDNF protein load is not associated with TrkB
receptor activity in APdE9 mouse cortex. TrkB receptor phosphor-
ylation (Y816) levels in the hippocampus, frontal cortex, parietal cortex
and temporal cortex of 12-month-old female APdE9 mice.
doi:10.1371/journal.pone.0068722.g007
Figure 8. BDNF protein accumulates around amyloid plaques in the brains of APdE9mice. A) Amyloid-b selective antibody W02 detects a
robust accumulation of amyloid-b in the brain of a 13-month-old APdE9 mouse. B) BDNF antibody reveals significant anti-BDNF immunoreactivity in
the cortex and hippocampus but not in the thalamus of aged APdE9 mouse, thus matching the regional pattern of Amyloid-b accumulation. C) A
magnified view of the framed area demonstrating doughnut-shaped anti-BDNF immunopositivity around amyloid plaques. D) The same BDNF
antibody dilution that was used to identify BDNF accumulation in the Amyloid-b plaques in APdE9 mouse brain did not show notable anti-BDNF
immunoreactivity in a wild-type mouse brain. A close-up of a single amyloid plaque in a APdE9mouse stained for (E) anti-BDNF, (F) anti-NGF, (G) anti-
CDNF and (H) GFAP to visualize activated astroglia. Only BDNF shows a donut-like staining pattern. Small arrows indicate plaque boundaries. (E–H)
Scale bar = 50 mm. Th= thalamus, HC=hippocampus, Ctx = cerebral cortex.
doi:10.1371/journal.pone.0068722.g008
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Supporting Information
Figure S1 Bdnf gene deficiency aggravates memory impairment
due to the APdE9 transgene in the Morris swim task. Male and
female mice are pooled. (A) Swim path length to the hidden
platform; *** significant APdE9 gene main effect (p,0.001,
ANOVA-rm), 11 Bdnf gene main effect (p = 0.008, ANOVA-rm),
###A+B- mice differ significantly from the AwBw control group
(p,0.001, Dunnett’s post-hoc test), ##A+Bw mice differ signifi-
cantly from the AwBw control group (p = 0.007, Dunnett’s post-
hoc test). (B) Thigmotaxis calculated as percent time spent in the
wall zone; *** significant APdE9 gene main effect (p,0.001,
ANOVA-rm), 111 significant Bdnf gene main effect (p,0.001,
ANOVA-rm), ### A+B- mice differ significantly from the AwBw
control group (p,0.001, Dunnett’s post-hoc test), ## A+Bw mice
mice differ significantly from the AwBw control group (p = 0.006,
Dunnett’s post-hoc test). Abbreviations for genotypes: AwBw=wt
x wt; AwB-=wt x Bdnf+/2; A+Bw=APdE9 x wt; A+B-=APdE9 x
Bdnf+/2.
(TIF)
Figure S2 Validation of BDNF protein analyses. (A) BDNF
antibody (sc-546) readily detects endogenous mature-BDNF
(straight line) and pro-BDNF (dash line) in the hippocampal tissue
of cleavage-resistant BDNF knock-in mouse (ki) whereas no pro-
BDNF is detected in wild-type (wt) mouse samples. Human
recombinant mature-BDNF and pro-BDNF are loaded as controls
in right. Asterics mark for unspecific bands recognized by anti-
BDNF. (B) BDNF ELISA readily detects BDNF protein in
hippocampal tissues of wild-type (WT) mice whereas no signal
over background is observed in samples obtained from conditional
BDNF knock-out (KO) mice. (C) Increased levels of mature BDNF
protein are detected in hippocampal tissues obtained from mice
chronically treated antidepressant fluoxetine (0.08 mg/ml in
drinking water for 21 days, n = 8/group; for details see Ref. 35)
with employed western and ELISA methods. A sample from
conditional BDNF knock-out (KO) mice was run as control for
western blot analyses to confirm the specific band corresponding
to mature BDNF. Note that anti-BDNF recognizes an intense, but
unspecific, band around the level of pro-BDNF. Human
recombinant mature-BDNF and pro-BDNF are loaded as controls
in right. Asterics mark for unspecific bands recognized by anti-
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